Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $43.90 Analyst target: $70.44 Upside: 60.46%
Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which protein growth factor signaling plays a critical role. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.